Licensing · GCC · Announced 2 Sept 2026
Pinnacle Life Science → ADCAN Pharma
Licensing deal between Pinnacle Life Science (India) and ADCAN Pharma (United Arab Emirates), announced 2 Sept 2026. Value: Undisclosed.
Parties: Pinnacle Life Science Pvt. Ltd (India) → Adcan (United Arab Emirates)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- United Arab Emirates
- Therapeutic area
- Oncology
- Asset
- 12 oncology products
- Announced
- 2 Sept 2026
Our analysis
Executive summary.
Pinnacle Life Science — an Indian oncology-focused CDMO and subsidiary of Aarti Drugs — signed a strategic partnership with ADCAN Pharma to license 12 oncology products into the UAE, followed by a staged technology transfer to enable local manufacturing.
The full analysis is free to read with a work email on this page.
Source: ADCAN Pharma full release